Double-Masked Study of Photrex (Rostaporfin) Photodynamic Therapy in the Treatment of Age-Related Macular Degeneration
Phase 3
- Conditions
- Macular Degeneration
- Registration Number
- NCT00157976
- Lead Sponsor
- Miravant Pharmaceuticals
- Brief Summary
The purpose of this study is to confirm the efficacy and safety of rostaporfin (PHOTREX) photodynamic therapy (PDT) in the treatment of classic and occult subfoveal choroidal neovascularization (CNV) associated with age-related macular degeneration (AMD).
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- UNKNOWN
- Sex
- All
- Target Recruitment
- 660
Inclusion Criteria
Patients with age greater than or equal to 50 years with at least one subfoveal CNV membrane secondary to AMD that can be demonstrated by fluorescein angiography.
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- SINGLE_GROUP
- Primary Outcome Measures
Name Time Method Visual Acuity
- Secondary Outcome Measures
Name Time Method Angiographic changes
Trial Locations
- Locations (1)
Multiple Investigators
🇷🇴Bucharest, Romania